- Current report filing (8-K)
08 December 2009 - 6:18AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 7, 2009
NEUROBIOLOGICAL TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-23280
|
|
94-3049219
|
(State or other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
2000 Powell Street, Suite 800,
Emeryville, California
|
|
94608
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(510) 595-6000
|
NOT APPLICABLE
|
(Former name or former address if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On December 7, 2009, Neurobiological Technologies, Inc., a Delaware corporation (the
Company
), filed a Form 25
with the Securities Exchange Commission (the
SEC
) to affect the voluntary withdrawal of the listing of its common
stock from the NASDAQ Stock Market LLC (
NASDAQ
). Delisting from NASDAQ will become effective on December 17, 2009.
The Company intends to file a Form 15 with the SEC on or before February 15, 2010 to deregister the Companys common
stock under the Exchange Act of 1934, as amended. The Company expects the termination of registration will become
effective 90 days after the date of the filing of the Form 15 with the SEC. Upon filing of the Form 15, the Companys
obligation to file certain reports and forms with the SEC, including Forms 10-K, 10-Q, and 8-K, will be immediately
suspended.
Cautionary Statement About Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements about the Companys future expectations and plans
that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties, which could
cause actual results to differ materially from those anticipated. When used in this Current Report on Form 8-K, the
word will, intends, expects and other similar expressions are intended to identify such forward looking
statements. Further information on potential risk factors that could affect the Company, its business and its financial
results are set forth in the Companys filings with the SEC. The Company does not undertake any duty to update
forward-looking statements.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
Dated: December 7, 2009
|
|
|
|
|
|
|
|
|
|
|
|
NEUROBIOLOGICAL TECHNOLOGIES, INC.
|
|
|
|
|
|
|
|
By:
|
|
/S/ Matthew M. Loar
|
|
|
|
|
|
|
|
|
|
Matthew M. Loar
|
|
|
|
|
Vice President and Chief Financial Officer
|
3
Neurobiological (NASDAQ:NTII)
Historical Stock Chart
From Nov 2024 to Dec 2024
Neurobiological (NASDAQ:NTII)
Historical Stock Chart
From Dec 2023 to Dec 2024
Real-Time news about Neurobiological Technologies (MM) (NASDAQ): 0 recent articles
More News Articles